SciBase Holding AB (OSTO:SCIB) ROCE %: -180.77% (As of Mar. 2026)


OSTO:SCIB SciBase Holding AB OSTO:SCIB
50 GF Score
Price kr33.80
GF Value kr21.74
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB ROCE %?

SciBase Holding AB OSTO:SCIB +0.30% 50 ROCE % is -180.77% as of Mar. 2026. GuruFocus rates OSTO:SCIB with a GF Score™ of 50/100 and a GF Value™ of kr21.74 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SciBase Holding AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -180.77%.

SciBase Holding AB  (OSTO:SCIB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SciBase Holding AB ROCE % Related Terms

SciBase Holding AB ROCE % Historical Data

* Premium members only.

The historical data trend for SciBase Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciBase Holding AB ROCE % Chart

SciBase Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.49 -84.61 -142.16 -152.78 -265.00

SciBase Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -190.43 -232.58 -65.69 -330.54 -180.77
OSTO:SCIB
50GF Score
SciBase Holding AB OSTO:SCIB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SciBase Holding AB ROCE % Calculation

SciBase Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-86.676/( ( (61.731 - 23.511) + (52.169 - 24.973) )/ 2 )
=-86.676/( (38.22+27.196)/ 2 )
=-86.676/32.708
=-265.00 %

SciBase Holding AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-96.8/( ( (52.169 - 24.973) + (103.694 - 23.792) )/ 2 )
=-96.8/( ( 27.196 + 79.902 )/ 2 )
=-96.8/53.549
=-180.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -180.77% mean?
SciBase Holding AB (OSTO:SCIB) has a ROCE % of -180.77% as of Mar. 2026.
Is SciBase Holding AB's ROCE % too high?
SciBase Holding AB's current ROCE % is -180.77%. Overall, SciBase Holding AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's ROCE % compare to ABT and SYK?
SciBase Holding AB's ROCE % of -180.77% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciBase Holding AB's current ROCE % is -180.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr21.74, compared to a current price of kr33.80 — trading 55.5% above its estimated fair value. The current ROCE % is -180.77%. SciBase Holding AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current ROCE % is -180.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of kr33.80 is trading 55.5% above its estimated GF Value™ of kr21.74. GuruFocus considers SciBase Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:SCIB:

  • ROCE %: -180.77%
  • GF Value™: kr21.74 vs. price of kr33.80 (55.5% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SciBase Holding AB Business Description

Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
50GF Score

Get the complete analysis for OSTO:SCIB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.80
Price
kr21.74
GF Value